FDA advisory panel to reconsider Avandia safety

(Reuters) - A federal health advisory panel in June will reconsider safety data on GlaxoSmithKline Plc's Avandia diabetes drug, although the British drugmaker on Friday said it has not sought permission to make the nearly discontinued drug widely available again in the United States.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news